Status:
COMPLETED
Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker
Lead Sponsor:
Franklin D. Gaylis, MD Inc.
Conditions:
Urinary Retention
Benign Prostatic Hyperplasia
Eligibility:
MALE
50-90 years
Phase:
NA
Brief Summary
To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will alleviate urinary retention secondary to BPH in who have failed a voiding trial without a catheter. Followin...
Eligibility Criteria
Inclusion
- Males betewen the ages of 50 and 90 years of age.Written informed consent.
- Men with acute urinary retention attributed to bladder outlet obstruction caused by BPH, who have failed atleast 1 week trial of alpha blocker treatment.
- PSA level equal to or greater than 1.5ng/ml and equal to or less than 15 ng/ml.
Exclusion
- Urinary retention attributed to a neurogenic or myogenic bladder dysfunction.
- Use of psychotrophic medications.
- Use of antichollinergic medications.
- Prostate cancer.
- Allery to five alpha reductase inhibitors.
- Prior prostate surgery.
- Urethral stricture.
- Bladder calculi.
- Invasive bladder cancer.
- Inability to understand or agree with the requirements of the study.
- Any investigational drug received within 30 days prior of study entry.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00680680
Start Date
May 1 2004
End Date
February 1 2008
Last Update
May 20 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.